Literature DB >> 26309557

Decreasing cartilage damage in a rat model of osteoarthritis by intra-articular injection of deoxycholic acid.

Zhaowei Yan1, Jianbin Xiong2, Chunyang Zhao3, Chenhao Qin4, Chunyan He4.   

Abstract

BACKGROUND: The aim of this experimental study was to evaluate the effect of intra-articular injection of Deoxycholic acid (DCA) on articular cartilage and subchondral bone following induction of knee Osteoarthritis (OA) in a rat model.
METHODS: Twenty-four Sprague Dawley rats were randomized divided into 4 groups (n = 6). Eighteen of the 24 rats underwent surgical destabilization of the medial meniscus on the right knee joints to induce OA, were divided into 3 groups: DCA 30 mg/kg group, DCA 120 mg/kg group and OA group. The rats in DCA-treated groups were given intra-articular injections of DCA (30 mg/kg or 120 mg/kg) in the operated knees once per 3 days for 42 days. The rats in OA group given intra-articular injections of vehicle alone in the operated knees under the same conditions. The remaining 6 rats (sham-operation group) received sham operations on the right knee joints. 45 days postoperatively, all of the animals were euthanized for macroscopic, histological and radiographic analysis to evaluate the effect of DCA on OA and to determine its potential mechanisms.
RESULTS: The results showed that DCA attenuated the severity of OA by reducing macroscopic observation sores for femoral condyles and histological sores for articular cartilage. DCA also significantly decreased bone destruction and erosion of joint evaluated by radiographic examination. Furthermore, DCA could markedly reduce the release of MMP-1, MMP-3 and IL-1β in serum.
CONCLUSIONS: Intra-articular injection of DCA is beneficial for knee OA. It might repair and protect OA cartilage by delaying cartilage degeneration and impairing the function of inflammatory mediators. These findings highlight DCA might be a useful therapeutic agent for OA.

Entities:  

Keywords:  Deoxycholic acid; intra-articular injection; osteoarthritis; treatment

Year:  2015        PMID: 26309557      PMCID: PMC4538145     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  26 in total

1.  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.

Authors:  Michael E Farkouh; Howard Kirshner; Robert A Harrington; Sean Ruland; Freek W A Verheugt; Thomas J Schnitzer; Gerd R Burmester; Eduardo Mysler; Marc C Hochberg; Michael Doherty; Elena Ehrsam; Xavier Gitton; Gerhard Krammer; Bernhard Mellein; Alberto Gimona; Patrice Matchaba; Christopher J Hawkey; James H Chesebro
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

Review 2.  Matrix metalloproteinases: role in arthritis.

Authors:  Peter S Burrage; Kimberlee S Mix; Constance E Brinckerhoff
Journal:  Front Biosci       Date:  2006-01-01

3.  Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: associations with degenerative changes.

Authors:  L C Tetlow; D J Adlam; D E Woolley
Journal:  Arthritis Rheum       Date:  2001-03

4.  Role of interleukin-1 and tumor necrosis factor alpha in matrix degradation of human osteoarthritic cartilage.

Authors:  Masahiko Kobayashi; Ginette R Squires; Aisha Mousa; Michael Tanzer; David J Zukor; John Antoniou; Ulrich Feige; A Robin Poole
Journal:  Arthritis Rheum       Date:  2005-01

5.  MMP profile in paired serum and synovial fluid samples of patients with rheumatoid arthritis.

Authors:  I Tchetverikov; H K Ronday; B Van El; G H Kiers; N Verzijl; J M TeKoppele; T W J Huizinga; J DeGroot; R Hanemaaijer
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

6.  The in vitro effects of dehydroepiandrosterone on human osteoarthritic chondrocytes.

Authors:  H Jo; J S Park; E M Kim; M Y Jung; S H Lee; S C Seong; S C Park; H J Kim; M C Lee
Journal:  Osteoarthritis Cartilage       Date:  2003-08       Impact factor: 6.576

7.  Differential expression patterns of matrix metalloproteinases and their inhibitors during development of osteoarthritis in a transgenic mouse model.

Authors:  H J Salminen; A-M K Säämänen; M N Vankemmelbeke; P K Auho; M P Perälä; E I Vuorio
Journal:  Ann Rheum Dis       Date:  2002-07       Impact factor: 19.103

8.  Relationship of matrix metalloproteinases and their inhibitors to cartilage proteoglycan and collagen turnover: analyses of synovial fluid from patients with osteoarthritis.

Authors:  N Ishiguro; T Ito; H Ito; H Iwata; H Jugessur; M Ionescu; A R Poole
Journal:  Arthritis Rheum       Date:  1999-01

9.  Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib.

Authors:  M E Farkouh; J D Greenberg; R V Jeger; K Ramanathan; F W A Verheugt; J H Chesebro; H Kirshner; J S Hochman; C L Lay; S Ruland; B Mellein; P T Matchaba; V Fuster; S B Abramson
Journal:  Ann Rheum Dis       Date:  2007-04-05       Impact factor: 19.103

10.  Efficacy Evaluation of a New Hyaluronan Derivative HYADD® 4-G to Maintain Cartilage Integrity in a Rabbit Model of Osteoarthritis.

Authors:  Pierre Mainil-Varlet; Antonella Schiavinato; Murielle Marie Ganster
Journal:  Cartilage       Date:  2013-01       Impact factor: 4.634

View more
  2 in total

1.  Synthetic nanoscale electrostatic particles as growth factor carriers for cartilage repair.

Authors:  Nisarg J Shah; Brett C Geiger; Mohiuddin A Quadir; Md Nasim Hyder; Yamini Krishnan; Alan J Grodzinsky; Paula T Hammond
Journal:  Bioeng Transl Med       Date:  2016-11-18

2.  Curcumin reinforces MSC-derived exosomes in attenuating osteoarthritis via modulating the miR-124/NF-kB and miR-143/ROCK1/TLR9 signalling pathways.

Authors:  Bo Qiu; Xiongfeng Xu; Peng Yi; Yarong Hao
Journal:  J Cell Mol Med       Date:  2020-08-09       Impact factor: 5.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.